...
首页> 外文期刊>Retinal cases & brief reports >PHOTODYNAMIC THERAPY WITH VERTEPORFIN PLUS INTRAVITREAL BEVACIZUMAB FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA: 4 YEARS OF FOLLOW-UP
【24h】

PHOTODYNAMIC THERAPY WITH VERTEPORFIN PLUS INTRAVITREAL BEVACIZUMAB FOR CIRCUMSCRIBED CHOROIDAL HEMANGIOMA: 4 YEARS OF FOLLOW-UP

机译:用Verteporfin Plus玻璃体内贝伐单抗的光动力学治疗用于外接脉络膜血管瘤:4年的后续行动

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To report the anatomical and functional response of combined photodynamic therapy and intravitreal injection of bevacizumab in a patient with symptomatic circumscribed choroidal hemangioma. Methods: The patient received a single-session full-fluence photodynamic therapy immediately followed by an intravitreal injection of bevacizumab (1.25 mg/0.05 mL). Results: One week after combined therapy, an improvement of best-corrected visual acuity from count fingers to 20/60 and a significant decrease in subretinal fluid were noted. One month later, we observed decreased leakage on fluorescein angiography in all phases of the study. Three months after treatment, the best-corrected visual acuity improved to 20/ 25 and spectral domain optical coherence tomography scans showed return to normal foveal architecture with no subretinal fluid and completely flat tumor. These findings were maintained during 4 years of follow-up. Conclusion: Combination therapy was associated with a rapid and persistent resolution of subretinal fluid, improvement of best-corrected visual acuity, and visual stability at 4 years of follow-up.
机译:目的:报告患有症状脉络膜血管瘤的患者患者中复合光动力治疗和玻璃纤维子术的解剖学和功能响应。方法:患者接受单季度全面流量的光动力治疗,然后立即进行玻璃体内注射Bevacizumab(1.25mg / 0.05ml)。结果:组合治疗后一周,注意到从计数手指到20/60的最佳矫正视力的改善,并进行了显着降低的子局部流体。一个月后,我们观察到在研究的所有阶段都观察到荧光素血管造影泄漏。治疗后三个月,最佳矫正视力改善为20/25,光谱域光学相干断层扫描扫描显示出恢复正常的变形架构,没有分子液和完全平坦的肿瘤。在4年的随访期间,这些结果得到了维持。结论:组合治疗与超稳态流体的快速和持续分辨率相关,改善最佳矫正视力,并在4年后的视觉稳定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号